Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Aug 8, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study evaluated the safety and effectiveness of dual chimeric antigen receptor (CAR) T-cell therapy for patients with recurrent or hard-to-treat B-cell non-Hodgkin lymphoma (NHL). This study found that this treatment was safe and effective for these patients.

Some background

B-cell non-Hodgkin’s lymphoma (NHL) is one of the most common types of lymphoma. Chemoimmunotherapy remains the typical first-line treatment for patients. Although effective for many patients, some patients stop responding to treatment. Treatment for these patients is challenging.

CAR T-cell therapy uses genetically modified T-cells (immune cells) to help the immune system attack cancer cells. CAR T-cells can be made to target different molecules on the surface of cancer cells called antigens. Some studies suggest that combining CAR T-cells that target more than one antigen may help improve effectiveness. Whether this dual-target CAR T-cell therapy is safe and effective for patients with B-cell NHL is unclear.

Methods & findings

This study included 32 patients with recurrent or unresponsive B-cell NHL. All patients received CAR T-cell therapy targeting CD19/CD22, and 29 patients were included in the final analysis. Patients were followed up for an average of 8.7 months.

Overall, 79.3% of patients responded to treatment. 34.5% of patients had no signs of cancer after treatment (complete response). Patients survived an average of 6.8 months without tumor growth or spread.

Overall, 63.3% of patients were still alive 1 year after treatment. 40.0% of patients were still alive without tumor growth or spread. Among patients who achieved a complete response at 3 months after treatment, 100% of patients were still alive 1 year later, with 66.7% of patients free of tumor growth or spread.

At follow-up, 10 patients had disease progression. On average, relapse occurred at an average of 5.3 months after treatment.

Overall, 93.8% of patients had side effects. Low blood cell coutns were most common. 90.6% of patients developed cytokine release syndrome (CRS). This happens when many immune system molecules called cytokines are released into the blood. These molecules trigger a variety of symptoms in the body, like fever, nausea, and headache. Most cases were able to be resolved with treatment, but 28.1% of patients developed severe CRS. These patients also reported low blood pressure (25.0%), fever (15.6%), and low levels of oxygen in the blood (12.5%).

The bottom line

This study found that dual-target CAR T-cell therapy was safe and effective for patients with relapsed or recurrent B-cell NHL. 

The fine print

This study had a very small number of patients. More studies are needed to confirm these results.

Published By :

Frontiers in oncology

Date :

Jun 12, 2021

Original Title :

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

click here to get personalized updates